Page 385 - An Evidence Review of Active Surveillance in Men With Localized Prostate Cancer

Appendix Table C2.1. Eligibility criteria, follow-up protocols, triggers for intervention and definition of progression in cohorts of active
surveillance/ watchful waiting/other observational management strategies (continued)

Center, Country Eligibility criteria Followup or monitoring protocol Triggers for intervention/ Definition of
[PMID] active therapy progression
Enrollment year
UCSF, US 111 Prostate cancer Office visit w/DRE every 3 mo, PSA every 3 mo (usually), TRUS Implied that there was not a Increase in Gleason or
[18433013] diagnosis, no every 6-12 mo. specific protocol for PSA velocity >0.75
prior therapy at ≥2003: prostate biopsy every 12-24 mo intervention; active ng/mL/yr (also
>1991 another ≥2002: “regular” nurse practitioner contact to ensure treatment based on analyzed PSA
institution, surveillance compliance and address concerns and anxiety disease progression velocity >2 ng/mL/yr
primary therapy and PSA DT<2 yr.
AS or no Ultrasonography not
primary therapy used (too much
(surgery, inter-observer
radiation, variability in lesion
brachytherapy, size)
androgen Gleason upgrade to
ablation) within ≥4 (if (≤6 at
6 mo of diagnosis) or ≥4+3
diagnosis (if 3+4 at diagnosis);
Patients PSADT ≤2 or 3
selectively were yr 131
offered AS if Gleason ≥7 or ≥33%
they met the of cores or >50% of
following any core 132
diagnostic
criteria: PSA
<10 ng/mL,
Gleason sum
≤6, absence of
Gleason grade
4 or 5, cancer
involvement of
<33% of biopsy
cores, and
clinical T1/T2a
tumor

C-110